August 20, 2020 09:27 AM EDTUpdated September 24, 05:34 AM
China
Pharma

Sev­en PD-(L)1 play­ers could be vy­ing for a place on Chi­na's drug re­im­burse­ment list. How far will they go?

Amber Tong

New up­dates to the process of as­sem­bling Chi­na’s lat­est Na­tion­al Drug Re­im­burse­ment List could mean that sev­en ad­di­tion­al PD-(L)1 drugs …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times